biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Reasons Why Pharmas May Have Avoided Bioasis

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 21, 2023 4:30pm

242 Views

Post# 35507917

RE:Reasons Why Pharmas May Have Avoided Bioasis

If you are going to partner with a company it's nice to know that it's going to be around. Biotech is a long-term game. BTI has never been adequately capitalized and has a history of difficulty raising money. It has topped this off by going into debt. Then the worst biotech market in history. It has had frequent management changes and has never been able to advance a project to the clinic itself despite hopes of clinical trials long ago. BTI has never projected stability and confidence.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity